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Abstract
Background: No treatments are currently available that slow, stop, or reverse disease progression in established
multiple sclerosis (MS). The Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) trial tests the safety and
feasibility of treatment with a candidate cell-based therapy, and will inform the wider challenge of designing early
phase clinical trials to evaluate putative neuroprotective therapies in progressive MS. Illustrated by the MSCIMS trial
protocol, we describe a novel methodology based on detailed assessment of the anterior visual pathway as a
model of wider disease processes - the “sentinel lesion approach”.
Methods/design: MSCIMS is a phase IIA study of autologous mesenchymal stem cells (MSCs) in secondary
progressive MS. A pre-test : post-test design is used with healthy controls providing normative data for inter-
session variability. Complementary eligibility criteria and outcomes are used to select participants with disease
affecting the anterior visual pathway.
Results: Ten participants with MS and eight healthy controls were recruited between October 2008 and March
2009. Mesenchymal stem cells were successfully isolated, expanded and characterised in vitro for all participants in
the treatment arm.
Conclusions: In addition to determining the safety and feasibility of the intervention and informing design of
future studies to address efficacy, MSCIMS adopts a novel strategy for testing neuroprotective agents in MS - the
sentinel lesion approach - serving as proof of principle for its future wider applicability.
Trial registration: ClinicalTrials.gov (NCT00395200).
Background
Multiple sclerosis (MS) is the commonest neurological
cause of disability in young adults, affecting over 1.3
million people worldwide. It is a chronic multifocal and
multiphasic immune mediated disorder characterised
pathologically by inflammatory demyelination, axonal
injury and partial remyelination [1]. Although recent
evidence suggests that conventional disease modifying
approaches can mitigate demyelination and secondary
axonal loss resulting from focal inflammation if given
during a narrow therapeutic-window in nascent RR-MS,
[2,3] there are currently no therapies that slow, stop, or
reverse progressive axonal loss in established disease.
Mesenchymal stem cells (MSCs) are recognised as a
candidate in this respect due to evidence that they pro-
mote oligodendrogenesis both in vitro and in vivo, [4,5]
result in functional improvement in animal models of
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MS,[6,7] and confer benefit in non-neurological T-cell
driven autoimmune human disease [8].
Trial design for the assessment of putative neuropro-
tective agents in MS presents a range of challenges
including the need to identify patients who will benefit
from treatment as well as to provide information on the
mode of action of any intervention [9]. This requires
clinical trial protocols that differ from those used in the
evaluation of disease-modifying therapies in terms of
both participant selection and measurement(s) of effi-
cacy. Current methods for detecting neuroprotection are
limited to comparatively insensitive assessments of over-
all response. These composite measures risk failure to
detect subtle but nonetheless meaningful effects of inter-
vention on components of the disease process that drive
cumulative disability. Therefore, neuroprotective trial
design must aim to select outcomes that are informative
with respect to stages of the disease other than the
relapsing-remitting phase, and which demonstrate the
effects of targeting both immunological and neurobiolo-
gical components of the complex pathogenesis. This
requires a combination of clinical outcome measures to
register improved function in addition to the use of
paraclinical observations and novel biomarkers that can
inform on the mechanisms of therapeutic effect and
detect benefits that lie below clinical thresholds. Against
this background, we report the design and baseline
cohort characteristics of a phase IIA trial of autologous
MSC therapy as a putative neuroprotective therapy for
secondary progressive MS that uses novel approaches to
address these challenges. By providing a detailed metho-
dological description, we aim to inform the development
of trial design in the wider setting of neuroprotective
therapies for progressive MS.
Methods
Trial design
The MSCIMS Trial uses an 18-month pre-test : post-
test design with a single treatment of autologous
mesenchymal stem cells at 12 months. A parallel cohort
of normative controls was also recruited to determine
inter-session variability of assessment methods.
Trial Centres
The trial was conducted over two sites. Clinical assess-
ments were based at the Wellcome Trust Clinical
Research Facility, Cambridge, UK; imaging assessments
were carried out at the UCL Institute of Neurology,
London, UK.
Trial objectives
MSCIMS aims to establish the safety and feasibility of
autologous intravenous mesenchymal stem cell therapy
in multiple sclerosis (phase IIA). The primary objective
is to describe the safety profile over six months of intra-
venously administered autologous MSCs at a dose of 1 -
2 × 106 cells / kg in patients with multiple sclerosis.
The secondary objective is to explore the potential effi-
cacy over six months of intravenously administered
autologous MSCs at a dose of 1 - 2 × 106 cells / kg by
clinical, neurophysiological and imaging assessments.
Participant Selection
Patients were selected on the basis of having secondary
progressive MS and prior involvement of the afferent
visual pathway (table 1). Given its use as an outcome
measure, a lower limit for retinal nerve fibre layer
(RNFL) thickness was imposed to avoid a floor effect.
Recruitment
Participants were recruited from secondary care referrals
in the East Anglia and North-London regions of the
UK. Referral criteria were: clinically definite multiple
sclerosis; Expanded Kurtzke Disability Status Score
(EDSS) 2.0 - 6.5 inclusive; clinical evidence of optic
nerve involvement; not on Beta interferon or Glatiramer
acetate within 6 months of referral, and not previously
on other disease modifying therapies at any point.
MSC isolation, expansion, characterisation & pre-
administration safety checks
In compliance with JACIE (Joint Accreditation Commit-
tee ISCT [International Society for Cellular Therapy] -
EBMT [European Group for Blood and Marrow Trans-
plantation]) requirements, normal serology was con-
firmed for HIV 1 & 2, Hepatitis B, Hepatitis C, HTLV 1
& 2, Syphilis, and CMV less than thirty days before
bone marrow aspiration. Following demonstration of
normal platelet count, PT and APTT, bone marrow
aspiration was performed under local anaesthesia and
Table 1 Eligibility criteria
Clinically definite multiple sclerosis
Expanded Kurtzke Disability Status Score (EDSS) 2.0 - 6.5 inclusive
Clinical evidence of optic nerve involvement on history or examination*
Abnormal visual evoked potential from one or both eyes suggestive of
demyelination
Retinal nerve fibre layer (RNFL) thickness of at least 45 microns in one
eye
T2 lesion on MRI of optic nerve
Age 18 - 65 inclusive
Capacity to give consent
No serious underlying bleeding disorder
Not on Beta-interferon or Glatiramer acetate within six months of trial
entry and not previously on other disease modifying therapies at any
point
*Defined as history of optic neuritis, Unthoff’s phenomenon, or optic atrophy
on examination.
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sedation (with anaesthetic supervision) in an operating
theatre using standard techniques.
Clinical-grade mesenchymal stem cells were gener-
ated under good manufacturing practice conditions
using standard operating procedures based on the
European Group for Blood and Bone Marrow Trans-
plantation developmental committee [8]. Briefly, bone-
marrow mononuclear cells were separated by density
gradient centrifugation in Ficoll-Paque™ PREMIUM
(GE Healthcare UK Ltd, UK) as previously described
[10]. Washed cells were re-suspended in PBS/EDTA
(Miltenyi Biotec Ltd, UK) and cultured in Dulbecco’s
modified Eagle’s medium-low glucose (Invitrogen, UK)
supplemented with 10% foetal bovine serum (Hyclone,
Perbio Science, UK) and plated at a density of 1 × 108
cells per cell-factory (Nunc, Thermo Scientific, UK).
Cultures were maintained at 37°C in a humidified
atmosphere containing 5% CO2 in cell factories. When
the cultures were near confluence (>80%), cells were
detached by treatment with 0.25% trypsin-EDTA (Invi-
trogen, UK) and re-plated at 3.5 × 106 cells per cell
factory. When 2 × 106 cells /kg (of participant) or
more were obtained, MSCs were harvested and cryo-
preserved in 4.5% human albumin solution (BPL, UK)
with Dimethyl Sulphoxide (Origen Biomedical Inc.) at
a final concentration of 10%.
MSCs were characterised in accordance with Interna-
tional Society of Cellular Therapy (ISCT) recommenda-
tions [11]. Briefly, this included evidence of tri-lineage
differentiation potential (adipocyte, chondrocyte, osteo-
cyte) and flow cytometry assessment confirming expres-
sion of CD73, CD90, and CD105 surface molecules
(>95%) and absence of CD34, CD45, CD14, and CD3 (<
2%). Release criteria of mesenchymal stem cells for clini-
cal use included absence of contamination by pathogens
(as documented by aerobic and anaerobic cultures and
mycoplasma testing before release), and lack of any
genomic copy number changes by 1Mb resolution BAC
array comparative genomic hybridization (aCGH) per-
formed in the Dept. of Pathology, University of Cam-
bridge [12].
Intervention dose, route, and administration procedures
Participants received one treatment with autologous
MSCs administered intravenously at a dose of 1 - 2 ×
106 cells/kg. Administration was performed as a day-
case procedure following pre-medication with chlorphe-
niramine 10 mg, hydrocortisone 100 mg, and metoclo-
pramide 10 mg. Cryopreserved MSCs were thawed (≤ 4
minutes) and immediately infused over 15 minutes.
Administration (mean 167.2 ml, range: 89 to 246 ml)
was followed by infusion of normal saline (500 ml) over
4 hours. Participants were monitored clinically for evi-
dence of adverse reactions over a minimum of 4 hours.
Outcome selection & assessment schedule
In order to increase power to detect efficacy through
use of tailored outcomes, complementary eligibility cri-
teria and outcome measures were selected allowing
detailed assessment of participants with disease affecting
the afferent visual pathway. Study of the entire visual
pathway as a model of wider disease processes allows
the use of clinical and paraclinical outcomes that can
inform on aspects of both structure and function [13].
Participants were assessed at 12 (M-12) and 6 (M-6)
months before treatment, immediately prior to treat-
ment (M0), and at 3 (M3) and 6 (M6) months after
treatment. Assessment at each time point was split into
two visits with an interval of less than two weeks: clini-
cal assessment and visual evoked potentials were per-
formed in Cambridge, UK; MRI, optical coherence
tomography (OCT), and neuro-ophthalmological assess-
ments were performed in London, UK. In addition,
patients were reviewed weekly on four occasions follow-
ing treatment to assess immediate clinical response and
monitor blood parameters including: full blood count,
prothrombin time, accelerated partial thromboplastin
time, erythrocyte sedimentation rate, serum urea & elec-
trolytes, serum calcium and phosphate, serum albumin,
bilirubin, alanine transaminase, aspartine transaminase.
C-reactive protein, thyroid-stimulating hormone, com-
plement C3 & C4, lymphocyte subsets, and serum IgG,
IgA & IgM.
Clinical outcome measures
Detailed neurological and medical history was obtained
at screening and updated at each visit. Specific enquiry
for adverse events was performed and participants
encouraged to keep written records of interim events.
Clinical outcomes assessed at each visit were: Multiple
Sclerosis Impact Scale – 29 (MSIS-29), Beck’s Depres-
sion Inventory II (BDI-II), Addenbrooke’s Cognitive
Examination - Revised (ACE-R), Multiple Sclerosis
Functional Composite (MSFC), and EDSS. Neuro-
opthalmological outcomes assessed at each visit were:
Visual acuity using a retro-illuminated EDTRS chart,
Contrast Acuity using retro-illuminated Sloan charts,
Colour vision using the Farnsworth-Munsell 100-Hue
test, and Visual Fields by automated static perimetry
(Humphrey field analyser, 30-2 protocol).
Paraclinical outcome measures
Paraclinical outcome measures at each visit were: visual
evoked responses (VER), measures of RNFL thickness
and Macular Volume (MV) using optical coherence
tomography (OCT), and MRI measures of brain and
optic nerve. Whole and central field checkerboard pat-
tern reversal VERs were recorded using reversal achro-
matic checks subtending 60’ at the eye. OCT images
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were acquired with a time domain OCT (Stratus OCT
Model 3000; Carl Zeiss Meditec, Dublin, CA, USA). All
OCT imaging was performed by a single observer (MK).
RNFL images were acquired by taking three circular 3.4-
mm scans, centred on the optic disc, the mean of which
was used to express RNFL thickness (Fast RNFL thick-
ness protocol). The thicknesses of the quadrants of the
RNFL were automatically calculated by the OCT device
software. Macular thickness maps were acquired by
making six radial scans centred on the fovea, and by
construction of a map from these scans (Fast macular
thickness map scanning protocol). OCT images are
given a signal strength by the Stratus OCT device, with
a maximum of 10. OCT images were rejected if an indi-
vidual eye was < 7, the inter-eye signal strength differ-
ence was >2, or if the difference in signal strength
between baseline and follow-up scans was >2.
MR imaging methodology
MR images were acquired using a Siemens MAGNE-
TOM 3.0T Tim Trio scanner (Siemens, Erlangen,
Germany) with a twelve-element receiver head coil.
Total acquisition time was approximately 75 minutes,
extended to 130 minutes for the two visits involving
optic nerve diffusion tensor imaging (DTI) and func-
tional MRI (fMRI).
(i) Optic nerve imaging
Optic nerve lesions were identified using a fat saturated
turbo spin echo sequences acquired at two different
echo times: coronal oblique, TR = 2960 ms, TE1 = 12
ms, TE2 = 71 ms, number of averages = 4, matrix size =
512 × 384, field of view (FOV) = 24 × 18 cm2, in-plane
resolution = 0.5 × 0.5 mm2, 16 × 3.0 mm slices for
each, acquisition time = 4 minutes per sequence.
Optic nerve area was assessed using a fat saturated
short echo fast fluid attenuated inversion recovery (sTE
fFLAIR) sequence with the following parameters: TR =
1830 ms, TE = 13 ms, TI = 800 ms, matrix size = 384 ×
306, 22 × 18 cm2 FOV, in-plane resolution = 0.60 ×
0.60 mm2, 16 × 3 mm contiguous coronal slices, acqui-
sition time = 13 minutes. The mean cross sectional
intra-orbital optic nerve area was calculated by aver-
aging at least four slices of the intra-orbital segment,
using semi-automatic contouring with manual correc-
tion as previously described [14].
Optic nerve magnetisation transfer ratio (MTR) was
assessed by acquiring 3D gradient echo sequences with
and without MT pre-pulse: TR = 36 ms, TE = 3.0 ms,
number of averages = 2, flip angle = 12°, matrix size =
256 × 192, FOV = 19 × 14.25 cm2, in-plane resolution =
0.70 × 0.70 mm2, 60 × 1.5 mm contiguous coronal
slices, acquisition time = 16 minutes. Optic nerves were
contoured from chiasm to globe on the image acquired
without the MT pre-pulse using a semi-automatic
threshold based method with manual correction if
required. MTR maps were calculated on a voxel by
voxel basis and the contours transferred to the MTR
maps, allowing calculation of MTR after manual correc-
tion for mis-registration due to movement between
sequences with and without the MT pre-pulse.
Optic nerve diffusion tensor imaging (DTI) was per-
formed by acquiring 3D fat and fluid attenuated spin
echo single shot echo planar sequences: TR = 6 s, TE =
84 ms, TI = 1.2 s, matrix size = 128 × 64, FOV = 15 ×
7.5 cm2, in-plane resolution = 1.17 × 1.17 mm2, 16 × 4
mm contiguous coronal oblique slices, diffusion gradi-
ents were applied in six directions with b = 600 s/mm2
and one b = 0 image was also acquired, number of
averages = 40, acquisition time = approximately 28 min-
utes [15]. The seven diffusion-weighted volumes (one b0
plus six b = 600 s/mm2), were then eddy-current cor-
rected using the FSL software library http://www.fmrib.
ox.ac.uk/fsl and diffusion metrics calculated using the
Camino software package http://www.camino.org.uk
[16]. The DT was calculated on a voxel by voxel basis.
Square regions of interest (ROI) of fixed size (2 × 2 vox-
els [5.5 mm2]) were placed on the b0 image, guided by
maximum signal intensity and minimum standard devia-
tion. ROIs were then applied to the calculated para-
meter maps in order to determine quantitative diffusion
indices. Mean diffusivity (MD), axial diffusivity (AD),
radial diffusivity (RD), and fractional anisotropy (FA)
were calculated by averaging parameters across at least
three slices per optic nerve.
(ii) Brain
Axial T2-Proton density (PD) weighted dual echo turbo
spin echo sequences were acquired: axial, TR = 3 sec-
onds, TE1 = 11 ms, TE2 = 101 ms, matrix size = 192 ×
256, FOV = 24 × 18 cm2, in-plane resolution = 0.9 ×
0.9 mm2, 48 × 3 mm contiguous slices per echo (total
96 slices), acquisition time = 4 minutes. Hyperintense
lesions were contoured from the PD image using a
semi-automated threshold-based method, and cross-
checked with contouring of T2 weighted images.
Axial T1 weighted spin echo sequences were also
acquired: TR = 710 ms, TE = 8.5 ms, matrix size = 233
× 256, FOV = 22 × 22 cm2, in-plane resolution = 0.9 ×
0.9 mm2, 48 × 3 mm contiguous slices, number of
averages = 2, acquisition time = 5 minutes. T1 hypoin-
tense lesions were contoured using a semi-automated
threshold based method.
Brain atrophy imaging was performed by 3D T1
weighted Modified Driven Equilibrium Fourier Trans-
form (MDEFT) gradient echo sequences:[17-19] sagittal,
TR = 7.13 ms, TE = 2.33 ms, matrix size = 224 × 256,
FOV = 256 × 244 mm2, in-plane resolution = 1.0 × 1.0
mm2, 176 × 1 mm contiguous slices acquired in 12
minutes. Fully automated segmentation was performed
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for longitudinal assessment of atrophy using Structural
Image Evaluation using Normalisation of Atrophy
(SIENA); single time-point brain volumes were attained
using SIENAX [20].
Brain MTR measures were obtained using coronal
3D gradient echo sequences with and without MT pre-
pulse: TR = 26 ms, TE = 3.0 ms, flip angle = 10°,
matrix size = 256 × 160, FOV = 25 × 16 cm2, in-plane
resolution 1.0 × 1.0 mm2, 208 × 1.0 mm contiguous
slices, acquisition time = 20 minutes in total. The MT
images with and without pre-pulse, and the MDEFT
T1 images were orientated to the axial plane, re-sliced,
and registered to the PD-T2 image set. MTR maps
were generated from the registered data and the regis-
tered 3D T1 volumetric image segmentation performed
using SPM (Version 8)[21] with and without the
lesions masked using the lesion contoured PD image.
These extracted brain segments were applied to mask
the MTR map into grey and white matter segments.
These tissue MTR maps were then refined by applying
a lower threshold of 10 pu, and erosions for whole
brain & grey matter (1 voxel) and white matter (2 vox-
els), to remove partial volume voxels. T1 lesion masks
were also applied to allow generation of MTR histo-
grams for: whole brain (WB), grey matter (GM), white
matter (WM), normal-appearing grey matter (NAGM)
(GM with the lesions removed), normal appearing
white matter (NAWM), T2/PD-lesions, and T1 hypoin-
tense lesions. MTR histograms in controls were
obtained for: WB, GM, and WM.
Functional MR imaging was performed by acquiring
T2* -weighted images depicting blood oxygen level
dependent (BOLD) contrast: near axial (whole brain),
TR = 3940 ms, TE = 30 ms, matrix size = 64 × 64, FOV
= 192 mm, slice thickness = 3 mm. Four experiments of
5 minutes duration were performed using differing
visual stimulation patterns as previously described [22].
Briefly, in a five-minute experiment, the subject uses
binocular vision through red-green filter goggles to view
a projected monitor while lying in the scanner. A rever-
sing checkerboard pattern was shown for sixteen-second
epochs of red or green stimuli, alternating with sixteen-
second epochs of no stimulation. Red and green colour
patterns were presented randomly in order to avoid pre-
dictability. The red-green filters were reversed by swap-
ping the goggles between each five-minute session (ie. if
the first run had red filter for the right eye, this was
changed to green for the second run). Monocular stimu-
lation was achieved for each epoch by matching the col-
our of stimulus and filter so that the eye looking
through the red filter could only see the red checker-
board pattern while the other eye was unstimulated by
red (and vice versa for green). Each five-minute experi-
ment consisted of four epochs of green and four of red,
thus stimulating both eyes four times each. Attention
was monitored by a manual response task in the non-
stimulation epochs. Analysis was performed using Statis-
tical Parametric Mapping software (SPM 8.0, Wellcome
Trust Centre for Neuroimaging, UCL, London, UK).
Images were realigned, co-registered, and normalised to
the T1 volumetric image obtained at that session.
Images were then smoothed, and the experimental
model was specified. Effects were analysed for each eye
independently.
Data & Safety Monitoring
An independent data monitoring committee was
appointed following recruitment of the first participant
and instructed to review progress 4 weeks after treat-
ment of the first three participants and at six-month
intervals thereafter.
Blinding and data analysis
Optic nerve area, optic nerve MTR, and optic nerve DTI
based outcomes were assessed by observers blind to par-
ticipant status (pre/post-treatment). Lesional analysis
was performed shortly after image acquisition at each
visit. Brain volume, brain MTR, and fMRI analyses were
performed using automated methods with minimal
manual corrections; blinding was not therefore per-
formed. Group comparisons for baseline outcomes were
performed by Student’s t-test. Following trial comple-
tion, safety data will be analysed to assess whether the
post-intervention period is associated with an increase
in adverse events; and efficacy data will be analysed to
assess whether the post-intervention period is associated
with a difference in pre-defined outcomes. No interim
analyses are planned.
Ethical approval and trial-registration
The MSCIMS trial was granted ethical approval follow-
ing Research Ethics Committee review (07/Q0108/104)
and is registered with the NIH clinical trials database
(NCT00395200).
Results
Recruitment & retention of participants
Ninety-eight subjects were screened between November
2007 and June 2009, with fourteen (14.3%) meeting all
eligibility criteria (Figure 1). Three subjects declined par-
ticipation following detailed discussions and one partici-
pant withdrew consent shortly after recruitment for
personal reasons.
Participant characteristics
All participants in the treatment arm had secondary
progressive MS with mean disease duration of 14.4
years (SD 7.9). Mean age was 48.8 years (SD 4.1), sex
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ratio was 3:7 (F:M) (table 2). Nine participants had a
history of clinical optic neuritis, affecting 13 eyes (65%);
the remainder had electrophysiological evidence only for
optic nerve involvement. One participant had been pre-
viously treated with beta-interferon for one year with
treatment discontinued due to disease progression two
years before recruitment to this trial. Eight healthy con-
trols were also recruited, matched for age (mean 43
years [SD 3.5], Student’s t-test, p = 0.1124) and sex (2:6
[F:M], Fisher’s exact test, p = 0.618).
MSC culture results
MSCs were successfully isolated and cultured to the tar-
get dose from all bone marrow aspirates (mean total
cultured dose = 2.0 ×106 cells / kg; range 1.1 to 3.7
×106 cells / kg). Mean culture duration was 24 days
(range 20 to 30 days) with a mean cell-doubling time of
1.5 days (range 1.3 to 2.0 days). All MSC cultures were
characterised to ISCT definition criteria, had normal
karyotype by array-CGH, and no evidence of pathogenic
contamination.
Baseline assessment results
(i) Patient-based measures
Baseline results for patient-based outcomes in the treat-
ment group are shown in table 3 (table 3). Mean EDSS
was 6.1 (range 5.5 to 6.5). All patients had higher MS
Functional Composite (MSFC) disability scores than the
National Multiple Sclerosis Society (NMSS) Task Force
reference population mean (Mean MSFC z-score -1.5;
range -0.4 to -5.4). Eight patients had Beck’s Depression
Inventory-II scores in the range for minimal depression
(0 - 13), one patient scored in the range for mild
depression (14 - 19), and one patient scored in the
range for moderate depression (20 - 28).
(ii) Optic nerve-based measures
Baseline results for optic nerve-based outcomes are
shown in table 4. Visual evoked potentials were abnor-
mal in all treatment arm participants (18 of 20 eyes
showing changes consistent with demyelination). Retinal
nerve fibre layer thickness was reduced by 15.3% in
patients’ eyes with a previous history of optic neuritis or
Unthoff’s phenomenon (clinically affected) compared to
clinically unaffected eyes (Absolute values: 72.4 μm [SD
12.9 μm] vs. 85.5 μm [SD 10.2 μm]; p = 0.0399). Full-
field VER latency was prolonged by 18.7% in clinically
affected eyes compared to clinically unaffected eyes
(Absolute values: 136.3 ms [SD 15.2 ms] vs. 114.8 ms
[SD 7.1 ms]; p = 0.0045).
(iii) Comparative performance between patients and
controls
Normalised brain volume was reduced by 11.1% in
patients compared to controls (Absolute values: 1486 cm3
[SD 75 cm3] vs. 1671 cm3 [SD 53 cm3]; p < 0.00005).
Assessed for eligibility
(n = 98)
Eligible (n=14)
Ineligible (n=84)
Recruited (n=11)
Participation declined (n=3)
Bone marrow aspiration
performed (n = 10)
Consent withdrawn (n=1)
MSCs cultured to target dose
and cryopreserved (n = 10)
Proceeded to treatment (n = 10)
Figure 1 Recruitment and retention to treatment cohort.
Table 2 Participant characteristics for treatment cohort
Participant Age Sex MS
Phenotype
Duration of
MS (years)
EDSS at
entry
Clinical episode of
optic neuritis
Optic nerve
affected
Time elapsed since first clinical
episode of optic neuritis (years)
1 44 Male SPMS 19 6 Yes Right 19
2 51 Male SPMS 26 6 Yes Both 26 (left); 9 (right)
3 40 Female SPMS 13 6.5 No Left* 6
4 48 Male SPMS 27 6 Yes Left 27
5 48 Male SPMS 12 6.5 Yes Right 11
6 52 Male SPMS 18 6 Yes Right 18 & 13
7 53 Female SPMS 5 6 Yes Left 6
8 51 Male SPMS 7 5.5 Yes Both 2 (left); 7 (right)
9 46 Female SPMS 11 6 Yes Both 5
10 51 Male SPMS 6 6.5 Yes Both 6
SPMS = secondary progressive multiple sclerosis, EDSS = expanded Kurtzke disability status scale. *First episode of Uhthoff’s phenomenon 6 years prior to
recruitment.
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There were no significant differences in brain imaging
MTR measures between controls and patients although
there was a trend to higher MTR values in controls.
Whole brain (mean) MTR was reduced by 5.3% in patients
(Absolute values: 44.52 pu [SD 6.56 pu] vs. 47.02 pu [SD
4.48 pu]; p = 0.3976). Grey matter (mean) MTR was
reduced by 7.2% in patients (Absolute values: 35.20 pu
[SD 7.34 pu] vs. 37.95 pu [SD 5.14 pu]; p = 0.4061). White
matter (mean) MTR was reduced by 4.6% in patients
(Absolute values: 46.37 pu [SD 6.92 pu] vs. 48.63 pu [SD
4.49 pu]; p = 0.4623).
Optic nerve-based measures showed significant differ-
ences between patients and controls in measures of
RNFL average thickness and optic nerve area, and in
DTI measures of mean diffusivity, fractional anisotropy
and radial diffusivity (table 5).
Discussion
The MSCIMS trial aims to establish the safety and fea-
sibility of autologous intravenous mesenchymal stem
cell therapy in multiple sclerosis. In addition, it pro-
vides an opportunity to advance trial methodology for
the assessment of putative neuroprotective agents in
MS, and inform the design of subsequent trials to test
potential efficacy. Two aspects of design are of particu-
lar note due to their potential for wider application.
First, a pre-test : post-test design was chosen in order
to maximise the opportunity to inform on potential
efficacy in a small cohort with an unknown effect size.
Given that intra-individual variance in the rate of dis-
ease progression in MS measured clinically or radiolo-
gically is less than inter-individual variance, [23-25] the
advantage of using a pre-test : post-test design is to
increase the effect size between comparator groups
and therefore increase statistical power by 40-80% [26].
Second, differences between patients in terms of dis-
ease pathology, course, and phenotype represent a sig-
nificant challenge in MS clinical trials, necessitating
the use of multidimensional outcome scales that are
insensitive to small effect sizes, and serving to inflate
the sample size required to achieve adequate power
[27]. The MSCIMS trial uses complementary eligibility
criteria and tailored outcome measures to study thera-
peutic response in participants who have deficits in the
anterior visual pathway as a model of wider disease
processes. This “sentinel lesion” approach forms a
novel methodology for neuroprotective trials in MS
and the MSCIMS trial assesses proof-of principle for
its utility.
Table 3 Patient-based measures in treatment group
Mean SD Range
BDI-II score 8.2 7.6 1 - 25
MSIS-29 Physical score 66.3 9.5 51 - 80
MSIS Psychological score 20.7 5.2 11 - 27
EDSS 6.1 0.3 5.5 - 6.5
ACE-R score 92.4 5.9 85 - 100
MSFC (total) z-score -1.5 1.4 -5.4 - -0.4
MSFC (arm) z-score -1.5 0.6 -2.7 - -0.7
MSFC (leg) z-score -2.0 4.1 -13.7 - -0.3
MSFC (cognitive) z-score -0.9 1.1 -2.1 - 1.2
Normalised brain volume (ml) 1486 75 1361 - 1586
T2 lesion volume (cm
3) 40.5 30.1 3.4 - 99.5
T1 lesion volume (cm
3) 10.2 9.5 0.6 - 31.3
BDI-II = Beck’s Depression Inventory II; MSIS-29 = Multiple Sclerosis Impact
Score (29 - item); EDSS = expanded Kurtzke disability status scale; ACE-R =
Addenbrooke’s Cognitive Examination (Revised).
Table 4 Optic nerve-based measures in treatment group
Clinically
Affected
(mean, SD)
Clinically
Unaffected
(mean, SD)
p
Number of optic nerves (n) 14 6
LogMAR 0.15 (0.20) 0.15 (0.17) 0.9640
Sloan 25% 0.31 (0.26) 0.30 (0.20) 0.9746
Sloan 5% 0.66 (0.35) 0.53 (0.18) 0.4282
Sloan 1.25% 1.0 (0.46) 0.75 (0.15) 0.1544
FM-100 Square-Root Total
Error Score
16.0 (4.4) 13.5 (2.8) 0.2188
Visual field Mean Deviance -4.28 (2.04) -3.04 (2.06) 0.2267
RNFL average thickness
(microns)
72.4 (12.9) 85.5 (10.2) 0.0399
Macular volume (mm3) 6.1 (0.5) 6.6 (0.3) 0.0624
Full field VER latency
(milliseconds)
136.3 (15.2) 114.8 (7.1) 0.0045
Full-field VER amplitude
(microvolts)
4.8 (1.9) 4.5 (2.3) 0.7669
Optic nerve area (mm2) 8.1 (1.3) 8.9 (1.1) 0.1961
Optic nerve MTR (pu) 28.4 (2.9) 31.3 (2.3) 0.0515
Optic nerve DTI Mean
Diffusivity (×10-3 mm2/s)
1.17 (0.29) 1.25 (0.26) 0.5415
Optic nerve DTI Fractional
Anisotropy (×103)
298.2 (91.2) 353.3 (88.6) 0.2282
Optic nerve DTI Radial
Diffusivity (×10-3 mm2/s)
0.99 (0.26) 1.03 (0.24) 0.7004
Optic nerve DTI Axial
Diffusivity (×10-3 mm2/s)
1.53 (0.42) 1.70 (0.35) 0.4012
FM-100 = Farnsworth-Munsell 100-Hue test; RNFL = Retinal Nerve Fibre Layer;
VER = Visual Evoked Response; DTI = Diffusion Tensor Imaging.
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In order to establish the safety profile of the interven-
tion, selection and timing of appropriate outcomes has
been guided by the published literature on intravenous
MSC therapy. Immediate adverse events consistent with
type I hypersensitivity (pruritis, rash, fever) are reported
in approximately 10% of subjects following intravenous
administration of autologous or allogeneic MSCs. Inten-
sive monitoring for evidence of allergic reactions is
therefore scheduled around the time of infusion. Med-
ium and long-term adverse event risks are less well
characterised from the published literature, but include
a theoretical risk of increased susceptibility to infection
and neoplasia. Weekly assessment (×4) following infu-
sion is designed to specifically screen for the former,
and long term monitoring the latter. Given that the
majority of the published cohort of patients who have
undergone treatment with intravenous MSCs have been
treated in the context of haematological malignancy, fol-
low up of the MSCIMS trial cohort offers a unique
opportunity to define long-term safety in a group with
longer life-expectancy and a lower background rate of
disease complications.
The treatment cohort in this trial is typical of patients
with established progressive MS in terms of disability
levels at recruitment and low relapse frequency (two
participants in the treatment group experienced episodic
clinical disease activity). While this group is appropriate
for safety-assessment of novel therapies, it may be sub-
optimal for assessment of therapeutic efficacy in later
phase trials. Given that the assessment of neuroprotec-
tion requires efficacy endpoints based on demonstrating
a reduction in the rate of neurodegeneration, a group
showing dynamic (active) progression may be preferable
in order to avoid type II error. Alternatively, in cohorts
with more modest rates of neurodegeneration/progres-
sion, longer follow up may be required to achieve suffi-
cient power. Two recent reports have described the use
of intrathecally delivered autologous MSCs in MS with-
out adverse events or significant change on global clini-
cal outcomes [28,29]. However, this may reflect the
significant challenge of demonstrating neuroprotection
with global outcomes in small early phase clinical trials
and a disease characterised by clinical and pathological
heterogeneity. Against this background, we propose that
an approach targeting a clinically articulate system with
a range of tailored outcomes, as illustrated by the
MSCIMS trial methodology, offers increased sensitivity
to demonstrate structural and functional change in
response to a putative neuroprotective intervention.
Conclusions
The MSCIMS trial represents a novel approach for eval-
uating neuroprotective therapies in MS. It will establish
the initial safety profile and feasibility of the interven-
tion, allow informed design of subsequent studies to
address efficacy, and test the utility of a novel methodol-
ogy for neuroprotective trials in MS with potential for
wider future application.
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PATIENTS CONTROLS
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(mean, SD)
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(mean, SD) p*
Number of optic nerves (n) 14 6 16 -
RNFL average thickness (microns) 72.4 (12.9) 85.5 (10.2) 101.6 (12.1) 0.0093
Macular volume (mm3) 6.1 (0.5) 6.6 (0.3) 6.9 (0.4) 0.1211
Optic nerve area (mm2) 8.1 (1.3) 8.9 (1.1) 10.3 (0.8) 0.0123
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Optic nerve DTI Axial Diffusivity (×10-3 mm2/s) 1.53 (0.42) 1.70 (0.35) 1.58 (0.23) 0.4809
RNFL = Retinal Nerve Fibre Layer; VER = Visual Evoked Response; DTI = Diffusion Tensor Imaging. * Significance test for control vs. patient by 2-way ANOVA
controlling for optic nerve status in patient group (clinically affected/unaffected).
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